First percutaneous transcatheter aortic valve‐in‐valve implant with three year follow‐up

Abstract

The CoreValve prosthesis has maintained proper function up to 3 years, with no structural deterioration or migration. Treating mixed aortic valve disease with predominant AR is feasible. The concept as well as durability of the first PHV-in-PHV has also been demonstrated.